Abstracts Archive - Page 2433 of 2607 - ACR Meeting Abstracts

Abstract Number: 2579 • 2012 ACR/ARHP Annual Meeting
Novel Autoantibodies to 14-3-3 Eta Are Highly Specific for Rheumatoid Arthritis
Walter P. Maksymowych¹, Désirée van der Heijde², R. Landewe³, Vivian P. Bykerk⁴ and Anthony Marotta⁵, ¹Department of Medicine, University of Alberta, Edmonton, AB, Canada, ²Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Division of Clinical Immunology and Rheumatology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, ⁴Rheumatology, Hospital for Special Surgery, New York, NY, ⁵Augurex Life Sciences Corp, North Vancouver, BC, Canada
Background/Purpose: Serum 14-3-3 eta, a protein biomarker that is differentially expressed in rheumatoid arthritis (RA), has been reported to add incrementally to rheumatoid factor (RF)…
Abstract Number: 2580 • 2012 ACR/ARHP Annual Meeting
Marginal Zone Defects in Wiskott-Aldrich Syndrome Are Dependent On B Cell Intrinsic Toll-Like Receptor Signals
Shaun W. Jackson¹, Nikita Kolhatkar², Marc A. Schwartz², Socheath Khim¹ and David J. Rawlings³, ¹Seattle Children's Research Institute, Seattle, WA, ²Department of Immunology, University of Washington, Seattle, WA, ³Pediatrics/Immunology, Washington, Seattle, WA
Background/Purpose: Patients with the primary immunodeficiency Wiskott-Aldrich syndrome (WAS) have severe abnormalities in splenic marginal zone (MZ) anatomy and function. Consistent with this, WAS patients…
Abstract Number: 2581 • 2012 ACR/ARHP Annual Meeting
Anti- Citrullinated Protein Antibodies but Not Rheumatoid Factor Are Associated with Larger Bone Erosions in rheumatoid arthritis patients- a Cross-Sectional Micro Computed Tomography Study
Carolin Hecht¹, Stephanie Finzel¹, Matthias Englbrecht¹, Sarah Schmidt¹, Juergen Rech², Elizabeth Araujo¹ and Georg Schett¹, ¹Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ²Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany
Background/Purpose: Anti- citrullinated protein antibodies (ACPA) are known to be associated with joint destruction and a more severe disease course in rheumatoid arthritis (RA) patients.…
Abstract Number: 2582 • 2012 ACR/ARHP Annual Meeting
Bone Anabolic Changes Progress in Psa Patients Despite Treatment with Methotrexate or Tumour Necrosis Factor Inhibitors
Stephanie Finzel¹, Sebastian Kraus¹, Sarah Schmidt¹, Axel J. Hueber², Juergen Rech³, Klaus Engelke⁴, Matthias Englbrecht¹ and Georg Schett¹, ¹Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ²Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ³Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany, ⁴Institute of Medical Physics, University of Erlangen, University of Erlangen-Nuremberg, Erlangen, Germany
Background/Purpose: To investigate whether methotrexate (MTX) or tumour necrosis factor inhibition (TNFi) affect osteophyte formation in patients with psoriatic arthritis (PsA). Methods: 41 patients with…
Abstract Number: 2583 • 2012 ACR/ARHP Annual Meeting
Bone Structure and Perfusion Quantification of Bone Marrow Edema and Pannus Tissue Areas in the Wrist of Patients with RA
Jose R. Teruel Antolin¹, Andrew J. Burghardt², Julien Rivoire¹, Waraporn Srikhum¹, Susan M. Noworolski³, Thomas M. Link¹, John B. Imboden⁴ and Xiaojuan Li⁵, ¹Musculoskeletal Quantitative Imaging Research Group, Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA, ²Department of Radiology & Biomedical Imaging, Musculoskeletal Quantitative Imaging Research, UCSF, San Francisco, CA, ³Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA, ⁴Department of Medicine, Division of Rheumatology, UCSF, San Francisco, CA, ⁵Department of Radiology and Biomedical Imaging, Musculoskeletal Quantitative Imaging Research, UCSF, San Francisco, CA
Background/Purpose: Bone marrow edema (BME) has been suggested as a strong predictor for erosive progression in RA joints, however, no previous studies examined the bone…
Abstract Number: 2584 • 2012 ACR/ARHP Annual Meeting
Quantitative and Semi-Quantitative Bone Erosion Assessment On High-Resolution Peripheral Quantitative Computed Tomography in Rheumatoid Arthritis
Waraporn Srikhum¹, Warapat Virayavanich¹, Andrew J. Burghardt², Andrew Yu¹, Thomas M. Link¹, John B. Imboden³ and Xiaojuan Li⁴, ¹Musculoskeletal Quantitative Imaging Research Group, Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA, ²Department of Radiology & Biomedical Imaging, Musculoskeletal Quantitative Imaging Research, UCSF, San Francisco, CA, ³Department of Medicine, Division of Rheumatology, UCSF, San Francisco, CA, ⁴Department of Radiology and Biomedical Imaging, Musculoskeletal Quantitative Imaging Research, UCSF, San Francisco, CA
Background/Purpose: The goals of this project were (i) to develop novel quantitative and semiquantitative measures of bone erosions at the metacarpophalangeal (MCP) and wrist joints…
Abstract Number: 2585 • 2012 ACR/ARHP Annual Meeting
Magnetic Resonance Imaging Versus Dual Energy Computed Tomography for Detection of Joint Pathology in Gout
Fiona M. McQueen¹, Anthony Doyle², Quentin Reeves³, Angela Gao³, Amy Tsai³, Gregory Gamble⁴, Barbara Curteis¹, Megan Williams⁵ and Nicola Dalbeth⁶, ¹Molecular Medicine and Pathology, University of Auckland, Auckland, New Zealand, ²University of Auckland, Auckland, New Zealand, ³Radiology, Auckland District Health Board, Auckland, New Zealand, ⁴Department of Medicine, University of Auckland, Auckland, New Zealand, ⁵Rheumatology, Auckland District Health Board, Auckland, New Zealand, ⁶Medicine, University of Auckland, Auckland, New Zealand
Background/Purpose: Magnetic resonance imaging (MRI) captures joint inflammation and damage in gouty arthropathy and can also reveal tophi. We have investigated reader reliability for scoring…
Abstract Number: 2546 • 2012 ACR/ARHP Annual Meeting
Tofacitinib Inhibits Radiographic Progression in Patients with Rheumatoid Arthritis Prone to Develop Structural Damage: A Post-Hoc Analysis of a Phase 3 Trial
Désirée van der Heijde¹, Robert B. M. Landewé² and David Gruben³, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Academic Medical Center/University of Amsterdam & Atrium Medical Center, Amsterdam, Netherlands, ³Pfizer Inc., Groton, CT
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor being investigated as a targeted immunomodulator and disease-modifying therapy for RA. In the ORAL Scan trial…
Abstract Number: 2547 • 2012 ACR/ARHP Annual Meeting
Weekly Subcutaneous Abatacept Confers Comparable Onset of Treatment Response and Magnitude of Efficacy Improvement Over 6 Months When Administered with or without an Intravenous Abatacept Loading Dose
M. Schiff¹, R. Alten², M. Weinblatt³, P. Nash⁴, Roy Fleischmann⁵, P. Durez⁶, J. Kaine⁷, I. Delaet⁸, S. Kelly⁸, M. Maldonado⁸, S. Patel⁸ and M. C. Genovese⁹, ¹University of Colorado, Denver, CO, ²Schlosspark-Klinik, University Medicine, Berlin, Germany, ³Rheumatology & Immunology, Brigham & Women's Hospital, Boston, MA, ⁴University of Queensland, Brisbane, Australia, ⁵University of Texas Southwestern Medical Center, Dallas, TX, ⁶Université Catholique de Louvain, Brussels, Belgium, ⁷Sarasota Arthritis Research Center, Sarasota, FL, ⁸Bristol-Myers Squibb, Princeton, NJ, ⁹Stanford University, Palo Alto, CA
Background/Purpose: To compare clinical and functional responses with SC abatacept administered with or without an IV loading dose, in pts with active RA and inadequate…
Abstract Number: 2548 • 2012 ACR/ARHP Annual Meeting
Global Molecular Effects of Tocilizumab Therapy in Synovial Biopsies of Early Rheumatoid Arthritis Patients
Julie Ducreux¹, Adrien Nzeusseu Toukap², Frédéric A. Houssiau¹, Patrick Durez³ and Bernard Lauwerys³, ¹Institut de Recherche Expérimentale et Clinique, Pôle de Maladies Rhumatismales, Université catholique de Louvain, Brussels, Belgium, ²Pôle de Maladies Rhumatismales, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium, ³Department of Rheumatology, Université catholique de Louvain, Brussels, Belgium
Background/Purpose: Rheumatoid arthritis (RA) is a chronic, systemic autoimmune inflammatory disease that is characterized by the presence of inflammatory cytokines, including interleukin-6 (IL-6). Here, we…
Abstract Number: 2549 • 2012 ACR/ARHP Annual Meeting
Induction of Remission in Patients with up to 12 Months of Moderate-to-Severe Rheumatoid Arthritis Symptoms Treated with Etanercept Plus Methotrexate Over 52 Weeks
Paul Emery¹, Mohammed Hamoudeh², Oliver FitzGerald³, Bernard Combe⁴, Stefanie Gaylord⁵, Theresa Williams⁵, Jack Bukowski⁶, Ronald Pedersen⁵, Andrew S. Koenig⁷ and Bonnie Vlahos⁵, ¹Department of Rheumatology, Leeds General Infirmary, Leeds, United Kingdom, ²Department of Medicine - Rheumatology, Hamad Medical Corporation, Doha, Qatar, ³Department of Rheumatology, St.Vincent's University Hospital, Dublin, Ireland, ⁴Department of Rheumatology, Lapeyronie Hospital, Montpellier, France, ⁵Department of Specialty Care, Pfizer Inc., Collegeville, PA, ⁶Department of Specialty Care, Pfizer Inc, Collegeville, PA, ⁷Pfizer, Inc., Collegeville, PA
Background/Purpose: In the COMET study, etanercept (ETN) plus methotrexate (MTX) therapy in patients with early rheumatoid arthritis (RA) yielded high clinical remission rates,1 but whether…
Abstract Number: 2550 • 2012 ACR/ARHP Annual Meeting
Clinical, Radiographic, and Immunogenic Effects After 1 Year of Tocilizumab-Based Treatment Strategy with and without Methotrexate in Rheumatoid Arthritis: The ACT-RAY Study
Maxime Dougados¹, Karsten Kissel², Philip G. Conaghan³, Emilio Martin-Mola⁴, Georg A. Schett⁵, Howard Amital⁶, Ricardo M. Xavier⁷, OM Troum⁸, Corrado Bernasconi⁹ and T.W.J. Huizinga¹⁰, ¹Rheumatology B Department, Paris-Descartes University, APHP, Cochin Hospital, Paris, France, ²F. Hoffmann-La Roche Ltd, Basel, Switzerland, ³University of Leeds, Leeds, United Kingdom, ⁴Rheumatology, Hospital Universitario La Paz, Madrid, Spain, ⁵Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁶Sheba Medical Center, Tel-Hashomer, Israel, ⁷Rheumatology Division, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil, ⁸Medicine, USC Keck School of Medicine, Santa Monica, CA, ⁹Consultant, Basel, Switzerland, ¹⁰Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: 24-week data from ACT-RAY comparing an add-on strategy (tocilizumab [TCZ] + methotrexate [MTX]) with a switch strategy (TCZ + placebo [PBO]) in MTX-IR patients…
Abstract Number: 2551 • 2012 ACR/ARHP Annual Meeting
Validation of EULAR Primary Sjögren’s Syndrome Disease Activity and Patient Indexes
Raphaèle Seror¹, Elke Theander², Johan G. Brun³, Manel Ramos-Casals⁴, Valeria Valim⁵, Thomas Dorner⁶, Xavier Mariette⁷, Hendrika Bootsma⁸, Athanasios G. Tzioufas⁹, Roser Solans-Laqué¹⁰, Jacques-Eric Gottenberg¹¹, Eric Hachulla¹², Wan-Fai NG¹³, Stefano Bombardieri¹⁴, Roberto Gerli¹⁵, Takayuki Sumida¹⁶, Alain Saraux¹⁷, Matija Tomsic¹⁸, Roberto Caporali¹⁹, Roberta Priori²⁰, Kathy Moser Sivils²¹, A.a. Kruize²², Cristina F. Vollenweider²³, Claudio Vitali²⁴ and Simon J. Bowman²⁵, ¹Rheumatology, Bicetre university hospital, LE Kremlin-Bicetre, France, ²Dept of Rheumatology, Skane University Hospital, Lund University, Malmö, Sweden, ³Department of Rheumatology, Haukeland University Hospital, Bergen, Norway, ⁴Laboratorio de Enfermedades Autoinmunes Josep Font, Hospital Clínic, Barcelona, Spain, ⁵Clínica Médica - Reumatologia, Universidade Federal do Espírito Santo, Vitória, Brazil, ⁶Department of Medicine/Rheumatology and Clinical Immunology and German Rheumatism Research Centre Berlin (DRFZ), Charité University Medicine Berlin, Berlin, Germany, ⁷Rheumatology, Université Paris-Sud, Le Kremlin Bicetre, France, ⁸Department of Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, ⁹Pathophysiology, School of Medicine, National University of Athens, Athens, Greece, ¹⁰Internal Medicine, Senior Consultant, Barcelona, Spain, ¹¹Rheumatology, Strasbourg University Hospital, Strasbourg, France, ¹²Department of Internal Medicine, Claude Huriez University Hospital, Lille, France, ¹³Departement of rheumatology, New-Castle University Hospital,, Departement of rheumatology, New-Castle University Hospital, UK, Newcastle, England, ¹⁴Department of Clinical and Experimental Medicine, Rheumatology Unit, University of Pisa, Pisa, Italy, ¹⁵Rheumatology Unit, University of Perugia, Perugia, Italy, ¹⁶Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba City, Japan, ¹⁷Department of rheumatology and unit of immunology (EA 2216), Université Brest Occidentale, Brest, France, ¹⁸Department of Rheumatology, University Medical Centre Ljubjana, Ljubljana, Slovenia, ¹⁹Division of Rheumatology, IRCCSPoliclinico S. Matteo Foundation, Pavia, Italy, ²⁰Department of Internal Medicine and Medical Specialties, Sapienza University, Rome, Italy, ²¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²²Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²³Rheumatology, German Hospital, Buenos Aires, Argentina, ²⁴Casa di Cura di Lecco, Lecco, Italy, ²⁵Department of Rheumatology, Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom
Background/Purpose: To validate the EULAR scores for assessment of primary Sjögren's Syndrome (SS): the EULAR SS Disease Activity Index (ESSDAI), the EULAR SS Patient Reported…
Abstract Number: 2552 • 2012 ACR/ARHP Annual Meeting
Clinically Significant and Biopsy-Documented Renal Involvement in Primary Sjögren’s Syndrome: Clinical Presentation and Outcome
Andreas V. Goules¹, Ioanna P. Tatouli², Alexandros A. Drosos³, Fotini N. Skopouli⁴, Haralampos M. Moutsopoulos⁵ and Athanasios G. Tzioufas⁶, ¹Pathophysiology, National University of Athens, Athens, Greece, ²School of Medicine, National University of Athens, Athens, Greece, ³Rheumatology Clinic, Department of Internal Medicine, Professor of Medicine/Rheumatology, Ioannina, Greece, ⁴Harokopion University, Athens, Greece, ⁵Department of Pathophysiology, School of Medicine, University of Athens, Athens, Greece, ⁶Pathophysiology, School of Medicine, National University of Athens, Athens, Greece
Background/Purpose: Primary Sjögren’s syndrome (pSS) may affect kidneys, causing either interstitial nephritis (IN) or glomerulonephritis (GMN). However, overt renal disease in pSS is rare and…
Abstract Number: 2553 • 2012 ACR/ARHP Annual Meeting
Histological, Serological and Clinical Changes in Response to Abatacept Treatment of Sjögren’s Syndrome
Sabine Adler¹, Meike Koerner², Frauke Foerger³, Marco-Domenico Caversaccio⁴ and Peter M. Villiger⁵, ¹Rheumatology, University Hospital Bern, Bern, Switzerland, ²Pathology, University Hospital Bern, Bern, Switzerland, ³Rheumatology, Inselspital-University Hospital, Bern, Switzerland, ⁴Ear Nose and Throat, University Hospital Bern, Inselspital, Bern, Switzerland, ⁵Rheumatology, Immunology and Allergology, University Hospital Bern, Bern, Switzerland
Background/Purpose: To prospectively evaluate histopathologic, blood and clinical responses to abatacept treatment in patients with primary Sjögren’s syndrome (pSS). Methods: Blood, saliva and minor salivary…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].